Stay updated with breaking news from Talk Positive. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Seeking more data on adjuvant alectinib in patients who have resectable ALK-positive non–small cell lung cancer (NSCLC), investigators compared outcomes vs chemotherapy.
The FDA has granted Priority Review to oral ALK inhibitor Alecensa (alectinib) for patients with early-stage ALK-positive non-small cell lung cancer.
Patients with ALK-positive, early-stage non-small cell lung cancer obtained significant improvement in disease-free survival.
/PRNewswire/ -- LUNGevity Foundation is partnering for the third time with the patient-led registered nonprofit organization ALK Positive to support the...
/PRNewswire/ -- LUNGevity Foundation is partnering for the third time with the patient-led registered nonprofit organization ALK Positive to support the...